News Related to Renin-Angiotensin System (RAS) Inhibitor

Related coverage linked through entity extraction aliases.

Novartis Reports Final ALIGN Trial Data Showing Vanrafia Slows Kidney Decline in IgAN

Feb 16, 2026

Novartis announced final Phase III ALIGN trial results showing Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy, with a 2.39ml/min/1.73m² eGFR difference versus placebo at week 136.

Novartis Vanrafia Phase III Data Show Slowing of Kidney Function Decline in IgA Nephropathy

Feb 13, 2026

Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.